Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]

Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]

Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017;356:j4. [Ref.ID 101389]

Rodrigo-Troyano A, Mediavilla MM, Garin N, Güell R. Insuficiencia cardíaca secundaria a tratamiento con itraconazol. Med Clin (Barc) 2017;148:69-70. [Ref.ID 101341]

Roustit M, Genty C, Lepelley M, Blaise S, Fromy B, Cracowski J-L, Bosson J-L. Amiloride treatment and increased risk of pressure ulcers in hospitalized patients. Br J Clin Pharmacol 2016;82:1685-7. [Ref.ID 101027]

Anónimo. Sacubitril/valsartan for chronic heart failure. Australian Prescriber 2016;39:221. [Ref.ID 101024]

Anónimo. FDA adds warning of abuse potential for medications treating low testosterone. DIA Daily 2016:1. [Ref.ID 100855]

Anónimo. Sacubitril + valsartan et insuffisance cardiaque chronique. Prescrire 2016;36:645-50. [Ref.ID 100816]

Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, on behalf of the Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016;354:i4857. [Ref.ID 100756]

Gislason GH, Torp-Pedersen C. NSAIDs and the failing heart. BMJ 2016;354:i5163. [Ref.ID 100755]

Whittle J. Blood pressure variability and cardiovascular risk. BMJ 2016;354:i4190. [Ref.ID 100604]

Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 2016;354:i3477. [Ref.ID 100598]

Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]

Angermann CE, Gelbrich G, Störk S, Gunold H, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G, for the MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression. The MOOD-HF randomized clinical trial . JAMA 2016;315:28 de junio. [Ref.ID 100501]

Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Kefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD, for the PARADIGM-HF Investigators. Influenze of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:1-8. [Ref.ID 100489]

Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G, for the MOOD-HF Study Investigators in Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA 2016;315:2683-93. [Ref.ID 100475]

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodríguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright Jr JT, Pajewski NM, for the SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged =75 years: a randomized clinical trial. JAMA 2016;315:2673-82. [Ref.ID 100474]

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suárez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-51. [Ref.ID 100415]

Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med 2016;164:705-14. [Ref.ID 100414]

Anónimo. Sacubitril valsartan for heart failure. Drug Ther Bull 2016;54:66-9. [Ref.ID 100402]